Pages

Friday, December 10, 2021

Was Trump Right? UV Light Therapy Shows Promise in COVID Patients

President Trump has been maligned and defamed for more than a year based on the lie that the “disinfectant” he mentioned during a COVID press conference was bleach. 
The fake news did that. 
They turned the word “disinfectant” into bleach before our very eyes and hardly anyone noticed. 
Here’s the transcript of what the president actually said and how a reporter then twisted it. 
Supposing we hit the body with a tremendous — whether it`s ultraviolet or just very powerful light, and I think you said that hasn`t been checked, but you`re going to check it. And then I said supposing you brought the light inside the body, which you can do either through the skin or in some other way, and I think you said you`re going to test that too. 
Sounds interesting… 
And then I see the disinfectant, where it knocks it out in a minute. One minute. And is there a way we can do something like that, by injection inside or almost a cleaning? Because you see it gets in the lungs and it does a tremendous number on the lungs. So it would be interesting to check that. So, that, you`re going to have to use medical doctors with. But it sounds interesting to me. 
Here's what has now been accomplished: 
A safety study was completed in December of 2020 by Aytu BioScience for its trademarked technology called Healight. The study was for investigative purposes prior to being submitted to the FDA for approval and publication. 
The results of the study, which claimed positive results, were then published in May of last year, but the 24-hour all-panic-all-the-time media didn’t cover it. Bloomberg did and a few other industry magazines. 
This single center, U.S.-based study evaluated the safety and proof of principle of the Healight device in newly intubated critically ill patients on mechanical ventilation diagnosed with COVID-19…. 
The Healight technology platform employs proprietary methods of administering intermittent ultraviolet (UV) A light via a novel respiratory tract device. Pre-clinical findings indicate the technology’s significant impact on reducing a wide range of viral and bacterial loads, including the coronavirus HCoV-229E, which is associated with the common cold. 
Recently published pre-clinical data have been the basis of discussions with the FDA for a path to enable human use for the potential treatment of SARS-CoV-2 in intubated patients in the intensive care unit (ICU).

GO READ THE WHOLE THING

No comments:

Post a Comment